Genelux

The potential for re-sensitizing cancer to previously effective treatments opens up new options in the battle against Platinum-Resistant/Refractory Ovarian Cancer (PRROC).

Genelux

Genelux to participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024 on Tuesday August 6th at 12 PM ET!

This conference is being hosted by BTIG, a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services.

BTIG’s Corporate Access program hosts client events across the consumer, digital assets, energy and infrastructure, financials, healthcare, real estate and technology sectors.

To join the conference, email [email protected].

We're committed to advancing cancer care as we continue to progress in our trials for ovarian and lung cancers. Stay tuned for updates as we continue our mission to improve patient outcomes!

Genelux Corporation (Nasdaq: GNLX) is a late-stage clinical biotech company advancing oncolytic immunotherapies for the treatment of hard-to-treat cancers, including Ovarian Cancer and Lung Cancer. Visit our website to learn more about our development of novel therapies that are designed to give hope back to patients.

For more, visit www.Genelux.com

We are honored to be part of this great nation and are committed to serving our community with dedication and excellence.

Cheers to 248 years of Independence. Happy 4th of July!

As we actively contribute to the collective effort in combating cancer, it is important to acknowledge and honor all the courageous cancer survivors during the month of June, recognized as .

People are the heart and soul of our endeavors. The Genelux team is committed to advancing next-generation oncolytic immunotherapies, tailored to orchestrate a personalized, multi-faceted attack to overpower the intricate defense mechanisms of tumors.

To all the brave cancer survivors, the Genelux family salutes you!

Did you know Olvi-Vec has been studied in multiple early and mid-phase clinical trials via regional and systemic deliveries, as a monotherapy and in combination with other therapies, in approximately 150 patients with a variety of cancer types?

Visit the clinical trials page on our website to learn more: https://loom.ly/iSzGph8

Are you eligible to participate in the OnPrime study? Check the eligibility criteria to see if you qualify.

This trial is open to women diagnosed with platinum-resistant/refractory ovarian cancer, including fallopian tube and primary peritoneal cancer.

Learn more here: https://loom.ly/dKh8gxQ

Genelux was thrilled to partner with Clearity Foundation for an insightful discussion around Platinum Sensitive/Resistant/Refractory Ovarian Cancer treatment options and clinical trials.

Watch the full video now!

Platinum Resistant Refractory Ovarian Cancer - Despite limited options, there is reason for hope Dr. Ramez Eskander, MD, Chief Scientific Advisor and Dr. Anne Mette Buhl, PhD, Director of Science and Clinical Trials welcome special guest, Dr. Alberto Men...

Get straightforward details about platinum-based chemotherapy drugs and how they are used to treat front-line and recurrent ovarian cancer — plus other useful info for patients and caregivers — via a free guide sponsored by Ovarian Cancer Research Alliance and offered by the National Comprehensive Cancer Network. Access it at nccn.org/patients/guidelines/content/PDF/ovarian-patient.pdf.

Get clear-cut info about different chemotherapy drugs for ovarian cancer, insights on what to expect before and after treatment, and tips on how to manage chemotherapy side effects: bit.ly/451LePz. Please share these resources with those who may need them.

Are you or someone you know considering a clinical trial for ovarian cancer treatment? It's a significant decision that could potentially offer access to cutting-edge therapies. Clinical trials play a crucial role in advancing medical knowledge and improving patient outcomes. Check here to see if the ongoing OnPrime trial is right for you or a loved one experiencing late-stage ovarian cancer.
For more information, click here: https://loom.ly/sRJEJE8

**UPDATED TIME**

Join us on Tues, June 4, 11:00-11:45AM PDT

Platinum Resistant Refractory Ovarian Cancer (PRROC): despite limited options, there is reason for hope.

Registration is free: https://bit.ly/4bEuHDo

​Special thanks to our sponsor Genelux for their support to make this event happen.

Join us on Tues, June 4, 12:00pm - 1:00pm PDT
Platinum Resistant Refractory Ovarian Cancer (PRROC): despite limited options, there is reason for hope.
Free Registration: https://bit.ly/4bEuHDo
​Special thanks to our sponsor Genelux for their support to make this event happen.

Read the latest press release here: https://loom.ly/ca6Qfqg

Today, we stand in solidarity with all those impacted by ovarian cancer. At Genelux, we're committed to advancing research and innovation to combat this disease. On , let's raise awareness, support those fighting, and continue our collective efforts towards early detection and effective treatments. Together, we can make a difference. 💙

Genelux recognizes new options are needed for late-stage ovarian cancer patients who failed prior treatments. Understanding the inclusion criteria is crucial for investigators determining who can participate in our clinical trial.

For more details on our ongoing trial, visit: https://loom.ly/nlwGIgY.

In Case You Missed It! The full replay of our Trailblazing Treatments virtual event is now available on the Genelux YouTube page.

Thank you to all who joined us for our first virtual symposium dedicated to the critical and challenging realm of platinum-resistant and refractory ovarian cancer.

This is an insightful exploration of the latest advancements, treatment strategies, and emerging options for patients navigating the complexities of 4th line setting and beyond with our esteemed KOLs, Dr. Robert Holloway, Dr. Premal Thaker, and Dr. Alberto Mendivil.

To watch the full video, visit https://loom.ly/oW-G__Q